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Abstract
We have previously shown that human embryonic stem cells can be differentiated into embryonic and fetal type of red
blood cells that sequentially express three types of hemoglobins recapitulating early human erythropoiesis. We report here
that we have produced iPS from three somatic cell types: adult skin fibroblasts as well as embryonic and fetal mesenchymal
stem cells. We show that regardless of the age of the donor cells, the iPS produced are fully reprogrammed into a
pluripotent state that is undistinguishable from that of hESCs by low and high-throughput expression and detailed analysis
of globin expression patterns by HPLC. This suggests that reprogramming with the four original Yamanaka pluripotency
factors leads to complete erasure of all functionally important epigenetic marks associated with erythroid differentiation
regardless of the age or the tissue type of the donor cells, at least as detected in these assays. The ability to produce large
number of erythroid cells with embryonic and fetal-like characteristics is likely to have many translational applications.
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Introduction
The development by the Yamanaka group of a method to
reprogram somatic cells into induced pluripotent stem cells (iPS)
by over expression of pluripotency factors hold considerable
promises for the development of stem cell therapies [1–5]. In the
mouse system, the differentiation potential of iPS has been tested
by chimera formation followed by germ line transmission [6–8]
and more recently by tetraploid complementation [9,10]. These
experiments univocally demonstrate that iPS are very similar to
embryonic stem cells since both cell types when placed in the
blastocyst environment can differentiate into full term mice.
However, several recent reports have shown that the expression
profile of iPS is subtly different from that of hES cells[11–13] and
that iPS might contains genetic mutations induced by the
reprogramming process itself. Similarly, the epigenetic profiles of
iPS has also been shown to differ from that of ES cells [14–20].
Despite these reports, whether ES and iPS are functionally
different remains unclear since hESC themselves are quite variable
because of their isolation and culture histories and because they
carry different genomes. The observation that multiple ES and iPS
cell lines can give rise to apparently normal mice suggests that the
epigenetic pluripotency program is relatively flexible and that
multiple epigenetic states are permissible during early develop-
ment maybe because reprogramming mistakes or epimutations
acquired in culture can be erased during the developmental
process. In the case of human iPS, in vivo experiments cannot be
performed to determine if a particular iPS clone is appropriately
reprogrammed because of obvious ethical reasons. Other means of
identifying fully reprogrammed iPS must therefore be devel-
oped[21]. One possible approach is to careful examined the in vitro
differentiation of iPS into well defined cell types and to compare
the results with that of hESC.
Human ES cells can easily be differentiated into hematopoietic
cells using a variety of methods [22–26]. We have previously
shown that human ES cells can be differentiated into hematopoi-
etic and red blood cells by co-culture on a feeder layer of
immortalized human fetal hepatocytes [23,27]. Importantly, we
found that in this system hESC differentiation closely recapitulates
early human erythropoiesis since we observed sequential expres-
sion of Hemoglobin Gower1 (f2e2), Hemoglobin Gower 2 (a2e2),
and Hemoglobin F (a2c2) but that they could produce only very
small amounts of Hemoglobin A (a2b2) [26,28–30]. The
proliferation potential of the erythroid progenitors and the
morphology of the erythroblast series obtained also mimicked
that seen in early development. The subtle switches in globins that
we observed in hESC therefore seemed very well suited to assess
reprogramming of iPS.
The first goal of the present study was to determine if iPS
differentiation into erythroid cells would follow the same patterns
as that observed for hESC and resullts in the sequential production
of progressively more developmentally mature red cells. The
second goal was to determine whether the age of the donors used
to produce iPS could influence the type of red cells produced in
our system. The third goal of the study was to assess the
differentiation potential of iPS into red blood cells because
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3differentiation of iPS into hematopoietic and mature erythroid
cells might have major translational applications.
To achieve these goals, we have produced iPS from somatic
cells of various ages and induced their differentiation using the
approach that we previously published for hESC. We found that it
was possible to produce large amounts of erythroid cells from iPS
and that the cells produced were very similar in their globin
expression patterns to the cells obtained by differentiation of hESC
regardless of the age of the donor of the cells. Therefore,
reprogramming with the four original Yamanaka pluripotency
factors leads to complete erasure of all functionally important
epigenetic marks, at least as detectable in our erythroid
differentiation system.
Results
Induced pluripotent stem cells were produced with viruses
expressing Oct-4, Sox2, KLF4 and c-Myc generously provided by
Dr Yamanaka. Viruses expressing either the human or the mouse
version of the four factors were tested. Three somatic cell types
were used: embryonic mesenchymal stem cells that were
previously derived from hESC [31,32], fetal liver mesenchymal
stem cells and adult skin fibroblasts that were derived in our lab.
Exponentially growing cells were infected with retrovirus express-
ing the four factors and iPS colonies were picked about 2 weeks
later based on morphology and expanded.
Colonies composed of tightly packed cells with a high nucleo-
cytoplasmic ratio and with the typical ES cell morphology could
be observed after two to three passages in hESC culture medium
(Figure 1A). To ascertain that these cells were indeed repro-
grammed to a pluripotent state, we first tested them by flow
cytometry using a panel of antibodies that are known to be
expressed at high levels in hESC [33]. This analysis revealed that,
as expected, most of the colonies obtained expressed high levels of
SSEA-3, SSEA4, TRA 1–60 and TRA 1–81(Figure 1B). Further
analysis by immuno-cytochemistry using anti Oct-4 antibodies
confirmed these studies since most colonies display a homogenous
nuclear staining for this ESC-restricted transcription factor
(Figure 1C). To characterize these iPS further and to ascertain
that individual colonies were indeed clonal, we evaluated the
integration patterns of the four reprogramming viruses using LM-
PCR from 10 of the iPS that had been derived from embryonic or
fetal liver mesenchymal cells. This analysis revealed that many of
the colonies that we had picked had different patterns of sites of
integration demonstrating that they were derived from indepen-
dent reprogramming events (Figure 1D and Table S1). These
iPSCs clones all had normal karyotyping (Figure 1E).
We then selected independent iPS clones and performed an
expression analysis at the transcriptional level. We first analyzed
reactivation of the Oct4 and Nanog genes by quantitative RT-
PCR and found that the levels observed in the iPS were within 2 to
6 fold the levels found for these genes in H1 and H9 cells when the
results were normalized with either GAPDH or b2-microglobulin
(Figure S1).
We then assessed the level of expression of the virally transduced
cDNA coding for the four pluripotency factors in 7 iPS clones
derived either from embryonic (E-iPS) or fetal liver (FL-iPS)
mesenchymal cells. The reprogramming factors must be silenced
at the end of the reprogramming process for the iPS to be
considered fully reprogrammed [1–3]. RT-PCR analysis revealed
that the iPS clones were not identical (Fig 2A): three clones had
undetectable levels of expression of the four factors (E-iPSA, FL-
iPSA and FL-iPSB); two clones (E-iPSB and C) respectively
exhibited small but detectable levels of the transgenic myc and
Oct4); one clone (FL-iPSD) expressed low levels of myc, Klf4 and
Oct-4 and interestingly, the virally-transduced four factors had
completely escaped silencing in clone FL-IPS C which expressed
high levels of all four of the virally-encoded factors.
To assess expression genome-wide, we then performed micro-
array experiments in which total RNA from 4 iPS were compared
with the H1 and H9 cell lines using Affymetrix Hu_Gene 1.0
arrays. H1 and H9 ES cells were at passage 50 to 80, while the iPS
were at passage 5 to 15. Biological replicates were performed for
all samples.
As shown in Figure 2B and S2, comparison of the iPS with the
two control hESC lines demonstrated that most of the genome of
the iPS was completely reprogrammed to an expression pattern
typical of pluripotent cells since we found that all the iPS tested
were as close to the H1 cell line (coefficient of correlation
between 0.990 and 0.995) than H1 is to H9 (r=0.989).
Clustering analysis confirmed these findings since we were
unable to get the H1 and H9 cells to cluster away from the iPS in
unsupervised analyses.
Interestingly, FL-IPS C, the iPS where the four factors were not
silenced, was indistinguishable in this assay from the iPS that had
completely silenced their transgenes (Figure S2). We conclude
from these experiments that the iPS that we produced with the
four factors were undistinguishable from ES cells in their
expression patterns, even when silencing of the virally transduced
factors is incomplete. Of course we cannot exclude subtle
differences between ES cells and iPS that would have been
undetected by our micro-arrays.
To further investigate potential differences between the iPS
caused by insertional mutagenesis, we examined in details
expression of the genes located 200 kb or less from an integration
site (Figure S3). Remarkably, we could not detect any effect of the
integration of the viruses in any of the iPS tested, even in FL IPS
C, the iPS where silencing of the four pluripotency factors did not
occur. This is surprising in light of previous studies in which we
had shown that randomly inserted transgenes could have dramatic
effects on expression of the neighboring genes [34–37]. This
discrepancy might be linked to the different regulatory elements
present in the virus backbone and in the transgenes that were used.
Having shown that we had produced iPS that were undistin-
guishable from undifferentiated ES cells by several criteria, we
examined their differentiation potential via the production of
embryoid bodies (EBs) followed by RT-PCR and by immnuno-
cytochemistry (Figure 2C and 2D). These studies revealed that
most of the iPS tested were able to produce cells from the three
germ layers, although some variability was observed between
clones. Figure S4 illustrates an RT-PCR analysis of 5 days EB
induced to differentiate into mesodermal, ectodermal, and
endodermal derivatives using various cytokine cocktails (see
methods).
We then tested whether the iPS that we generated could form
teratomas containing the three germ layers. As shown in
Figures 2E and S5 all clones of iPS tested showed the abilities to
form teratoma in NOD-SCID Gamma mice and all teratomas
tested were shown to contain cells from the three germ layers after
H and E staining.
To determine if iPS derived from embryonic, fetal or adult
tissues were able to differentiate into blood derivatives, we co-
cultured randomly selected iPS clones for each donor sources with
FhB-hTERT fetal hepatocytes since we had previously shown
[23,27,28] that this procedure efficiently leads to the production of
a CD34
+ cell population which contains a fraction of cells able to
differentiate into mature primitive and early definitive erythro-
cytes. A total 9 iPS lines were tested, three derived from embryonic
Red Blood Cell Differentiation from hiPSCs
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25761mesenchymal cells, three from fetal mesenchymal cells and three
from adult fibroblasts.
Figure 3A illustrates a FACS analysis of cells incubated for
increasing numbers of days with FHB-hTERT. The yield of
CD34
+ cells in multiple replicated experiments was quite variable
since it ranged between 1 and 9% for both the H1 and the iPS
lines but no statistically significant differences were observed. It is
noteworthy that for both the H1 control and for the various iPS
Figure 1. iPS characterization. A: Phase contrast micrograph illustrating the morphology of human iPS cells on Matrigel. B: FACS analysis.
Histograms illustrating expression of surface marker, SSEA-3, SSEA-4, Tra-1-60, and Tra-1-8 on ES and iPS cells. The black histograms represent the IgG
control. C: immuno-micrographs illustrating expression of transcription factor Oct3/4. Cells were permeabilized and stained with PE-labeled anti-Oct4
antibodies and with DAPI. Most cells in the iPS and the H1 colonies exhibited nuclear Oct3/4 expression D. LM-PCR analysis. Photograph of a 1%
agarose gel illustrating the result of an LM-PCR determination of integration site patterns. E: Karyotyping of iPS derived from different cell of origins.
doi:10.1371/journal.pone.0025761.g001
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+ cells produced increase linearly with
time in co-culture. This time dependence of the number of CD34
+
studies was not detected in our earlier studies [23,27,28].
Importantly, FL-IPS C, the iPS which had no silenced the four
transgenic factors differed from all other iPS because the
percentage of CD 34
+ cells produced was 10 to 15 times higher
than that of the H1 line or of the other iPS (Figure 3A). Therefore,
although, the global mRNA expression pattern of this iPS was
undistinguishable from that of the other iPS, FL-iPSC has a
strikingly different differentiation potential than the other iPS
either because of the ubiquitous expression of one or more of the
four factors, or because of some other epigenetic abnormality.
To determine if these iPS-derived CD34
+ cells could differen-
tiate into red blood cells, we cultured them in our 4-step liquid
culture system designed to amplify erythroid progenitors and
induce their differentiation into mature red blood cells. Again, 9
iPS lines were tested. As shown in Figure 3B and S6, these
experiments revealed that CD34
+ cells derived from iPS co-
cultured for 14 or 35 days with FHB-hTERT yielded erythroid
cells that did not enucleate and that had a primitive morphology
very similar to that of erythroid cells derived from H1 hESC in the
same conditions. Quantification of the number of cells confirmed
that iPS have an erythroid differentiation potential equivalent to
that of H1 cells: Plating of 100,000 hESC or iPS-derived CD34
+
cells yielded at the end of the liquid culture period varied between
0.5 and 8 million erythroid cells. This relatively large variation
could not be reduced despite efforts at standardization of the
experimental conditions and likely reflect the complexity of the
CD34
+ cells plated. No statistically significant differences were
detected between the iPS and the H1 line. However, because of
the experimental variations observed, we cannot exclude that a
much larger number of experiments would have revealed subtle
differences.
We then performed HPLC analysis on erythroblasts obtained
after 14 days and 24 days of liquid culture to determine globin
expression patterns since we had previously demonstrated that
H1-derived erythroblasts express predominantly Hb Gower 1 after
14 days of liquid culture, and Hb Gower 2, 10 days later.
Figures 3C and 3D, which respectively illustrates and summarizes
the results for the three embryonic, the three fetal and the three
adult iPS tested, demonstrate that iPS-derived erythroblasts
undergo the same globin switches during their maturation than
H1 cells. We conclude from these experiments that iPS are
reprogrammed to an embryonic hematopoietic potential regard-
less of the age of the donor. To determine if iPS could differentiate
into fetal-like red blood cells that can enucleate and express Hb F,
we then co-cultured 3 clones of iPS derived from embryonic
mesenchymal cells, 3 from fetal liver mesenchymal cells and 2
from adult skin fibroblasts for 35 days with FhB-hTERT, sorted
the CD34
+ cells, differentiated them in liquid culture for 24 days,
and performed a morphological and HPLC analysis. This revealed
that regardless of the age of the donor, the iPS could differentiate
into enucleated red blood cells that contain predominantly Hb F
and therefore that they are able to express an erythroid program
that is similar to that of hESC (Figure 3C and 3D).
Interestingly, CD 34
+ cells obtained from 14 or 35 days of
co-culture of FL-iPS C with FHB-hTERT were unable to
differentiate into erythroid cells. Since the CD34 antigen is
expressed on a wide variety of cell types [38–40], this result could
be explained either by the fact that these cells were not
hematopoietic or by the fact that they were hematopoietic but
unable to differentiate into the erythroid lineage. Vodyanik et al.
[41] have shown that ES cell-derived CD34+ cells that have
hematopoietic potential co-express CD43. We therefore assessed
CD 43 expression on FL-iPSC-derived CD34+ cells and on 2 iPS
clones (derived from adult skin) as well as on H1 derived cells
(Figure 3E). These experiments revealed that Fl-iPS C did not
express CD 43 suggesting that they are not hematopoietic By
contrast, the H1 and the iPS cells tested expressed CD 43 at low
level after the co-culture and at higher levels 7 days after the
beginning of the liquid culture. The CD45 marker could mostly be
detected on cells derived from 35 day co-culture.
This analysis of FL iPS C show that iPS that are undistinguish-
able from H1 by morphologically, surface antigen, expression
profiles and global gene expression pattern can be grossly
dysfunctional in their differentiation potential. Whether this is
due to over expression of one of the four factors or to another
epigenetic anomaly remains to be determined
Discussion
We have produced human iPS from embryonic, fetal, and
adult cells and demonstrated that they were similar to the H1 and
to the H9 ES cell lines by morphology, surface antigen
expression, global expression pattern and the ability to form the
three germ layers in in vitro and in vivo differentiation assays. We
have also shown that iPS differentiation recapitulates early
erythroid differentiation including two different globin switches to
the same extent than ES cells. Several groups have shown that
iPS can differentiate into erythroid cells[42–48]. We characterize
here for the first time globin expression patterns by HPLC after
differentiation of and show that they are very similar to those
observed after hESC differentiation. We therefore conclude that
human somatic cells can be fully reprogrammed to a pluripotent
state and that they do not retain any functional memory of their
previous differentiation and developmental state, at least as could
be detected in our assays. These conclusions are based on analysis
of embryonic and fetal mesenchymal cells, and of adult
fibroblasts. We cannot exclude that iPS produced from other
cell types might retain a memory. Others have shown that iPS do
retain an epigenetic memory but only at low passages numbers
[49,50].
Figure 2. Expression and differentiation analysis. A: Expression of the virally-transduced reprogramming factors cDNA. Y-axis represent
absolute number of copies of cDNA per ng of RNA determined using a standard curved based on a purified PCR product. Expression of the
transduced cDNA was mostly silent except for FL iPS C (see text). B: Global expression patterns: Scatter-plot illustrating an Affymetrix micro-array
analysis of iPS as compared to H1 and to parental somatic cells. Micro-array results were normalized by RMA. Average of two biological replicates is
plotted. Left scatter-plot illustrates expression of H1 and H9 cells, middle scatter-plot, expression of iPSA versus p51R parental cells and right scatter
plot expression of iPSA versus H1. iPS are undistinguishable from ES cells in this assay. All iPS were at least at passage 20 when the RNA were
extracted. C: Embryoid bodies. Phase contrast micrographs illustrating 5 days EB formed from iPS. D: Spontaneous differentiation: Immuno-
fluorescence micrographs illustrating iPS differentiation into the three germ layers. Two days EB were transferred to chamber slides containing ES
medium without bFGF. After 7 days, the differentiated cells were stained with FITC labeled antibodies against b-III-tubulin (ectoderm), a-smooth
muscle actin (mesoderm) and a-feto-protein (endoderm) and counter-stained with DAPI. Results from 2 different iPS are shown. (Bar=100mm). E:
Micrographs illustrating H and E stained slide of teratomas generated from an iPS. iPS can differentiate into teratomas containing the three germ
layers (see also Figure S5).
doi:10.1371/journal.pone.0025761.g002
Red Blood Cell Differentiation from hiPSCs
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25761Red Blood Cell Differentiation from hiPSCs
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e25761Analysis of FL-IPS C, The iPS that did not silence the
reprogramming viruses revealed that iPS with normal morphol-
ogy, and expression patterns could be grossly abnormal in their
differentiation process. Such iPS might prove a fertile experimen-
tal material to better understand the reprogramming process.
Finally, our ability to produce red blood cells with embryonic
and fetal phenotypes from iPS might prove useful to study early
human erythropoiesis and to test therapies for the hemoglobin-
opathies. However, our inability to produce adult red blood cells
from iPS or ES cells will limit the scope of these experiments to
diseases that affect genes expressed in those cells. Development of
techniques to produce red blood cells with an adult phenotype
from pluripotent embryonic cells is a critical step that remains to
be accomplished to unlock the full translational potential of these
cells.
Methods
Cell culture: P51R, and fetal Liver mesenchymal cells were
grown in DMEM containing 10%FBS, 1 mM L-glutamine
(Invitrogen), 1% Penicillin-streptomycin (P/S) and 1% MEM-
nonessential amino acids (Invitrogen). Human adult fibroblasts
were grown in RPMI-1640 contain 15% FBS, 1 mM L-glutamine
(Invitrogen), 1% Penicillin-streptomycin (P/S) amd 1% MEM-
nonessential amino acids (Invitrogen).
Human ES cell line H1, H9 and iPS cells were maintained in
two different conditions as undifferentiation cells. The first method
was by co-culture with p51R mesenchymal cells in Dulbecco
modified Eagle medium (DMEM)/F12 media (Invitrogen) sup-
plemented with 20% Knockout Serum Replacer (Invitrogen),
4 ng/mL Basic Fibroblast Growth Factor (bFGF, ProsSpecTany),
1 mM L-glutamine, 1% Penicillin –streptomycin (P/S) [31]. The
second method was on matrigel (BD) in DMEM)/F12 media
(Invitrogen) supplement with N2B27 medium, 0.5% Bovine
Serum Albumin (Sigma), 1 mM L-glutamine, 1% Penicillin –
streptomycin (P/S), 100 ng bFGF [51].
Retrovirus Production: All virus used in this study are
retrovirus. Retroviral expression plasmids containing the mouse
[1] or humans [2] 4 pluripotent genes, Oct4, Sox2, Klf4 and c-
Myc were obtained from Addgene. One day before transfection,
PhoenixAmpho packaging cells (Orbigen) were plated at a density
of 2610
6/ml in 10 cm cell culture dish with DMEM contain 10%
FBS. One day later, 10 ug of plasmid was transfected using
lipofectamine 2000 (Invitrogen) for 5 hours at 37uC. After 5 hours,
the supernatant was replaced with fresh medium contain 10% FBS
for another 12,24 hours. Supernatant was collected, filtered with
0.45 mm filter and store in 280uC.
Virus infection. Exponentially growing cells were infected
with the four factors in the presence of 6 ug/ml Polybrene(sigma-
Aldrich). After 24 hours, supernatant was discarded and replaced
with fresh DMEM medium with 10% FBS. Infected cells were
incubated for 5 days at 37uC in 5% CO2, dissociated with trypsin-
EDTA (Invitrogen) and transferred to 6 well plates pre-coated with
Matrigel containing DMEM and 10% serum. A day after the
medium was replaced with DMEM)/F12 media (Invitrogen)
supplemented with N2B27 medium, 0.5% human serum albumin
(Sigma), 1 mM L-glutamine, 1% Penicillin –streptomycin (P/S),
100 ng bFGF. Medium was then changed every other day until
iPS colonies were picked.
Differentiation of hESC/iPS to CD34+ cells: Undiffer-
entiated hESC/iPS cells on feeder plates were dissociated with
collagenase type IV (1 mg/mL; invitrogen), transferred onto
irradiated FH-B-hTERT feeder layers with DMEM supplemented
with 20% FBS (Invitrogen), 2 mM L-glutamine, 1% MEM-
nonessential amino acids, 100 u/mL penicillin and 100 mg/mL
streptomycin. The medium was changed every 2 to 3 days. For 35
days co-culture, cells were plated onto new feeder layers as above.
On day 14, 21, or 35 of co-culture, differentiated H1/iPS cells on
FH-B-hTERT were dissociated into single cell suspensions by
using collagenase IV followed by trypsin/EDTA or Tryple
Express (Invitrogen) supplemented with 5% chick serum. CD34
cell separations were performed using EasySep CD34 magnetic
beads according to the manufacturer’s instructions (StemCell
Technologies, Vancouver, BC).
Amplification and differentiation of CD34
+ cells.
CD34
+ cells obtained either from hESCS or from iPS then seeded
in the following 4-step system: In the first step (amplification of
progenitors), sorted CD34
+ cells were placed on a 12-well plate at
a density of 50,000 cells/mL with serum-free basal medium
StemSpan (StemCell Technologies) supplemented with Hydrocor-
tisone (10
–6 M), IL3 (13 ng/mL), BMP4 (13 ng/mL), Flt3L
(33 ng/mL), SCF (100 ng/mL), and EPO (2.7 U/mL) for 7 days.
In the second step (differentiation of progenitors to erythroid
lineage), the cells were transferred to StemSpan medium
supplemented with hydrocortisone (10
–6 M), IL3 (13 ng/mL),
BMP4 (13 ng/mL), SCF (40 ng/mL), EPO (3.3 U/mL) and IGF-
1 (40 ng/mL) for 7 days. Cell density was kept below one million
cells per mL at all time by adding fresh medium every 2 or 3 days
as needed.
HPLC: Erythroid cells were collected at different time points
from the liquid cultures, washed twice with PBS, and lysed in
water by 3 rapid freeze-thaw cycles. Debris were eliminated by
centrifugation at 16 000 g and the lysates stored in liquid nitrogen
before HPLC analysis. HPLC were performed as described [28].
Figure 3. Hematopoietic differentiation. A: Production of CD34 positive cells: hES and iPS cells were co-co-cultured for 7 to 35 days with FHB-
hTERT. Percentage of cell expressing CD34 was then assessed by FACS using FITC-labeled anti-CD34 antibodies. Most iPS produced similar level of
CD34
+ cells as H1 except FL iPSC which produced 10 to 15 times more CD34
+ cells. B: Giemsa staining of erythroid cells obtained by differentiation of
H1 or iPS-derived CD34
+ cells obtained from co-cultures with FHB-hTERT for 35 days. After the co-culture, the cells were placed in liquid culture for 14
days (first row) or 21 days (rows 2 and 3) and cytospins were performed. iPS-derived cells have morphologies very similar to ES-derived cells
regardless of the age of the donor. C: Chromatograms illustrating HPLC analyses of globins produced by ES or iPS derived erythrocytes. Top left
chromatogram: Erythrocytes produced after 14 days of FHB-hTERT co-culture and 14 days of liquid culture express mostly Hb Gower I (e2f2), bottom
left: after 10 more days of liquid culture (24D), erythroblast down-regulated f-globin leading to the production of Hb Gower 2 (e2f2). Erythroblasts
produced after 35 days of co-culture with FH-B-hTERT and 14 days (top right) or 24 days (bottom right) of liquid culture express mostly Hb F (c2a2). D:
Histograms summarizing HPLC results from 9 iPS clones (left) or from triplicated differentiation experiments of H1 ES cells (right). Erythroid cells
generated by co-culture of iPS on FhB-hTERT for 14 days exhibit a major f to a globins switching during their maturation from basophilic to
orthochromatic erythroblasts in liquid culture. Cell generated after 35 days of co-culture on FhB-hTERT express primarily gamma globins and have
therefore switched their expression of the b-like globin genes from e to c globin as compared to cells obtained after 14 days of co-culture. Globin
expression patterns of iPS-derived cells are very similar to what is observed with hESC. E: Flow cytometry data showing that H1 and SK-iPS after co-
culture with FHB-hTERT cells for 14 days cells differentiate into cells that express CD34 and CD43. By contrast, FL-iPS C-derived cells, express CD34 but
not CD43. After liquid culture ES and iPS-derived cells differentiate into cells that co-express CD34
+ and CD45
+. FL-iPS C do not proliferate.
doi:10.1371/journal.pone.0025761.g003
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washed, and resuspended in PBS with 1% FBS. The cells (1610
5/
ml) were then stained for 30 minutes on ice with saturating
amounts of fluorescein isothiocyanate (FITC)-conjugated or
phycoerythrin (PE)-conjugated monoclonal antibodies. Antibodies
recognizing the following human antigens were used:
CD34,CD43,CD235a, SSEA-4, (BD Pharmingen) and TRA-1-
60, TRA-1-81, SSEA-1, SSEA-4 (eBioscience).
Allanalysesweredoneona BectonDickinsonFACSCaliburlaser
flowcytometric system (BDBiosciences, SanJose, CA,http://www.
bdbiosciences.com) equipped with a Macintosh PowerMac G5
personal computer (Apple Computer, Inc., Cupertino, CA, http://
www.apple.com) using CellQuest Pro software (BD Biosciences).
Antibodies are described in details in Table S2.
Immunofluorescence. Cells were grown on chamber slide
coated with matrigel (BD), fixed with 4% paraformadehyde for 10
minutes at room temperature. Cells were permeabilized with 0.1%
Saponin(Sigma) in PBS for 10 minutes, stained with PE-
conjugated antibody against human Oct3/4 (BD Pharmingen),
or with unlabelled a-fetoprotein (R&D system), b-III-Tubulin or
a-smooth muscle actin. FITC-conjugated secondary antibodies
were used. Labelled slides were mounted in Prolong Gold antifade
prior to visualization under a fluorescence microscope (ZEISS,
AxioVert 200M). All antibodies are described in Table S3.
Cytospin and Giemsa staining: Cells were spun onto poly-
lysine–coated slides using a Cytospin 2 apparatus (Thermo
Shandon, Pittsburgh, PA). After drying for a minute, slides were
stained with Wright-Giemsa reagents (Hema 3 stain; Fisher
Scientific, Pittsburgh, PA) following the manufacturer’s instruc-
tions. Images were processed using ACT-2U version 1.6 software
(Nikon, Tokyo, Japan).
Teratoma Formation. iPS cells were obtained from feeder
cell plates by collagenase IV treatment (1 mg/mL). The iPS
colonies were cut with a glass pipette into small clumps. The
clumps were collected after they had settled to the bottom of the
tube for 5–10 minutes and resuspended with ES medium (100 uL/
wells of six well plate). The cell suspension was mixed with one-
third the volume of matrigel (BD Bioscience) and 10
6 cells were
injected intramuscularly into the hind leg of a 6–8 week old NSG
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice. After 6–12 weeks,
the visible tumors were dissected out and fixed in 10% formalin
solution overnight. The tissues were paraffin embedded, sectioned
and stained with hematoxylin/eosin using standard procedure.
RNA extraction, cDNA preparation, and RT-PCR.
Total RNA was isolated (RNeasy Mini Kit, QIAGEN) with
DNA elimination (RNase-Free DNase Set, QIAGEN). The RNA
was then ran on gel electrophoresis to assess for purity and was
then reverse transcribed to cDNA (SuperScript III First-Strand
Synthesis System for RT-PCR, Invitrogen). Gene expression was
assessed using quantitative real-time PCR (Applied Biosystems,
7900HT). PCR reactions were run in duplicates using a Qiagen
SYBR Green Kit. Controls with no primers and no template
cDNA were run for each PCR reaction. A control with no reverse
transcription was also run to ensure there was no genomic DNA
contamination. Gene expression was determined by relative
quantification with values corrected for GAPDH or B2M and
normalized relative to control cell. Primer sequences are described
in supplementary methods(Table S4 and S5).
Micro array analysis. Total RNA were hybridized to
Affymetrix HUGene ST 1.0 arrays. Data were normalized by
RMA using Affymetrix software and analyzed using Statgraphics
Centurion 15.2 (Statpoint Inc, Warrenton, VA) and Cluster 3.0
[52]. All data are MIAME compliant and can be downloaded
from NCBI GEO archives (GSE26946).
Supporting Information
Figure S1 Endogenous pluripotency factors expressed
in ES or iPS cells. Histograms illustrating a Q-RT-PCR analysis
of expression of the Pou5F (Oct4) and Nanog in control H1 and
H9 cells in Fetal liver mesenchymal cells (FL) in embryonic
mesenchymal cells (p51R) and in 7 iPS derived either from fetal
liver (FL-iPS A to D), from p51R (iPS A through C) or from skin
fibroblast (sk-iPS A). All iPS expressed detectable levels of the 2
endogenous transcription factors. Y axis represents the ratio of
expression of the factors compared with H1 as determined by the
Delta Ct method.
(TIF)
Figure S2 Comparison of the transcriptome of the H1
and H9 cell lines with that of four different iPS.
Comparison of the transcriptome of the H1 and H9 cell lines
with that of four different iPS. Biological replicates of each sample
were hybridized on Affymetrix Hu_Gene 1.0 arrays and the results
were normalized by RMA. Average of the biological replicates are
plotted.
(TIF)
Figure S3 Logarithm of expression of genes close to
integration sites of transduced reprogramming factors.
Histograms representing expression (determined by Affymetrix
array) of all the genes located within 300 kb of 4 of the 8
integration sites that we characterize in iPSA (white bars) as
compared to H1 (black bars). No significant differences could be
detected in more than 50 integration site analyzed in 4 different
iPS suggesting that the integrated viruses had minimal effects.
(TIF)
Figure S4 Forced differentiation. iPS were differentiated by
EB production followed by incubation for 5 days in either 100 ng/
BMP4; wnt3A, ActivinA and 0.5% FBS or 1 uM retinoic acid,
100 ng Noggin; RNA was then extracted and Q-RT PCR were
performed. Increase in expression of marker for the three germ
layers was detectable for almost all iPS. The level of induction
varied from experiment to experiments.
(TIF)
Figure S5 Teratoma formation of adult Skin iPS cells.
SkiPS cells formed teratoma in the NOD/SCID mice, showed the
pluripotency of iPS cells from adult skin fibroblasts. A: the size of
the teratoma was around 1 cm. B: the H&E staining showed that
the teratomas contain cells derived from the three germ layers.
(TIF)
Figure S6 Erythroid cells differentiation of HSC derived
from SKiPS cells. Hematopoietic cells derived from iPS after 14
or 35 days of co-culture with FhB-hTERT and 14 and 24 day of
liquid culture showed different morpholgies after Giemsa staining.
(TIF)
Table S1 Integration sites of four factors in iPS.
Integration sites were identified by inverse-PCR.
(DOCX)
Table S2 Antibodies used for FACS analysis.
(DOCX)
Table S3 Antibodies used for Immunocytochemistry.
(DOCX)
Table S4 RT-PCR primers for virus genes. For each gene,
top row is forward primer, bottom row is reverse primers. Sizes of
the amplicons are in bp.
(DOCX)
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each gene, top row is forward primer, bottom row is reverse
primers. Sizes of the amplicons are in bp.
(DOCX)
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